BioWorld

Feb. 14, 2008

Avastin Improves PFS Again in Phase III Breast Cancer Trial

A Phase III trial of Avastin (bevacizumab) in breast cancer met its primary endpoint of improving progression-free survival (PFS), but analysts remained split on whether the new data would be enough to gain FDA approval. (BioWorld Today) Read More

Inspire's Denufosol Starts 2nd Phase III Study in Cystic Fibrosis

Vertex Offerings Expected to Raise up to $405.8M

Panel: Good Communication Cuts Dangers of Shareholder Activism

Genzyme Barely Misses; Posts Strong Fourth-Quarter Sales

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2026.

New York University identifies new analogues of mannose-6-phosphate

BioWorld Science

New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...

FB-7033 demonstrates efficacy in MASH management

BioWorld Science

17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...

Illustration of antibody carrying radioactive isotope

Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

BioWorld Science

At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...

Bial-Portela discovers new OX1 receptor antagonists

BioWorld Science

Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...